Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments- Genor to lead clinical development, regulatory submissions and commercialization of...
-
RESEARCH TRIANGLE PARK, N.C., June 01, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company has entered into a debt...
-
- Trilaciclib significantly reduced myelosuppression and need for related supportive care interventions for patients with small cell lung cancer (SCLC) receiving chemotherapy - New Drug Application...
-
New Drug Application (NDA) submission for trilaciclib in small cell lung cancer on track for 2Q20Rintodestrant combination trial with palbociclib expected to initiate in 2Q20Management to host webcast...
-
RESEARCH TRIANGLE PARK, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...
-
RESEARCH TRIANGLE PARK, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca,...
-
- Jack Bailey appointed to Board of Directors- Soma Gupta joins as Chief Commercial Officer- Company reports inducement grant under Nasdaq Listing Rule 5635 (c)(4) RESEARCH TRIANGLE PARK, N.C.,...
-
New Drug Application (NDA) submission for trilaciclib in small cell lung cancer on track for 2Q20Trilaciclib selected for inclusion in I-SPY 2 breast cancer trialRintodestrant (G1T48) combination...
-
RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company will present corporate...
-
RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference...